SCHEMBL21751454

SCHEMBL21751454

O=c1c(Cc2ccc(O)cc2)nc2c(Cc3ccccc3)[nH]c(-c3cccc(O)c3)cn1-2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ PARP1 P09874 2/20 0.38
▸ CASR P41180 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ ABCB1 P08183 1/20 0.37
▸ CDC7 O00311 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KIF11 P52732 3/20 0.34
▸ CYP17A1 P05093 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ XDH P47989 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800148 1.00 ADORA3 (0.39) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL21751336 0.97 ADORA3 (0.41) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL21751359 0.93 ADORA3 (0.37) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL25760174 0.93 CASR (0.38) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL2680751 0.93 ABCB1 (0.40) ADORA3ADORA2AADORA1PARP1ALDH1A1
SCHEMBL10196910 0.92 PARP1 (0.38) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL19206714 0.92 ALDH1A1 (0.38) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL25760164 0.91 ADORA3 (0.37) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL25761034 0.91 ADORA3 (0.39) ADORA3ADORA2AADORA1PARP1CASR
SCHEMBL21751461 0.91 KDM4E (0.41) ADORA3ALDH1A1GAACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841173-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2021-06-30 — — EP claimed
US-20200062766-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-02-27 — — US claimed
WO-2020041579-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2020-02-27 — — WO claimed
EP-3981839-B1 COELENTERAZINE ANALOGS FOR USE IN LUCIFERASE-BASED ASSAYS PROMEGA CORP (US) 2025-08-20 — — EP disclosed
US-20240059697-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2024-02-22 — — US disclosed
WO-2024000408-A1 LUCIFERASE MUTANT AND USE THEREOF 青岛华大智造普惠科技有限公司 2024-01-04 — — WO disclosed
WO-2023123509-A1 MUTANT AND USES THEREOF 深圳华大生命科学研究院 2023-07-06 — — WO disclosed
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 — — US disclosed
EP-3841173-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2021-06-30 — — EP disclosed
WO-2020041579-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2020-02-27 — — WO disclosed
US-20200062766-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062766-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ADORA3 3089/4885ADORA2A 1970/4885ADORA1 4310/4885
US-11691976-B2 Coelenterazine analogues GLB1, SI, TCF7L2 ADORA3 3089/4885ADORA2A 1970/4885ADORA1 4310/4885
US-20240059697-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 ADORA3 3089/4885ADORA2A 1970/4885ADORA1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback